Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925199 | 0.98 | HRH3 (0.47) | HRH3RETDGAT1ACVR1CNR2 | |
| SCHEMBL6925410 | 0.95 | HRH3 (0.45) | HRH3DGAT1ACVR1CNR2FYN | |
| SCHEMBL6927559 | 0.91 | RAD52 (0.44) | HRH3DGAT1CNR2KCNH2 | |
| SCHEMBL6925668 | 0.86 | CNR2 (0.53) | CNR2HPGDHSD17B10FYN | |
| SCHEMBL6925048 | 0.85 | TDO2 (0.43) | HRH3DGAT1KCNH2 | |
| SCHEMBL6925885 | 0.85 | CNR2 (0.56) | CNR2HPGDHSD17B10 | |
| SCHEMBL6928201 | 0.84 | ADK (0.46) | RETDGAT1CNR2FYNKCNH2 | |
| SCHEMBL6925451 | 0.82 | FYN (0.54) | DGAT1FYNKCNH2 | |
| SCHEMBL6926636 | 0.81 | TSHR (0.46) | DGAT1CNR2HPGDHSD17B10FYN | |
| SCHEMBL6924500 | 0.81 | ATR (0.51) | RETACVR1CNR2HSD17B10KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | HRH3 816/4885RET 1562/4885DGAT1 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.